. . . . . "Paliperidone" . . . "Schizotypal personality disorder" . . . . . . "Similarly, De Cos Milas et al. [6] described their clinical experience with paliperidone in adolescents. They presented 3 males and 2 females, age between 15 and 17 years. Diagnoses were autism, borderline personality disorder, schizotypal personality disorder, personality disorder not otherwise specified, and schizophrenia. Prescribed dose was 3–9 mg/day, and actual mean time of treatment duration is 5.8 months. In 4 cases, paliperidone was initiated as a change from other antipsychotic. There were no adverse effects that required discontinuation and in all cases symptoms improved." . . . . . . . "Adolescents (15-17)" . . . "RSA" . "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCR9fz0fKCdWOWC+pxhkQhEM/ppbdIYe5TLSdj+lJzSlv9mYBaPgrzVezSwwbmhlHBPDZa4/vHycU315BdmUGq+pXllp9+rWFfrb+kBJwhZjpG6BeyyXBsRFz4jmQVxl/ZYHilQTh/XalYzKkEAyTiEMPee4Kz61PaWOKH24CsnOQIDAQAB" . "ONZ2cjHiYvujzxAAsURK4gDhLswbE1v/AtFzeBhybK/j5B4EbFUipnx1Ix5lODeB86s8RE6aDz1PZoQuMUej1as3WP7tUgDNvI/FRtSAp9W4rsRUpNVYuEmcvy83vrHpXXavUM70b0VOCsnNSN8LqOBjM29n8cA3uZ67Q7m7FNw=" . . "2022-09-16T11:50:48.517240"^^ . . . "2.3.0" .